Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seagen Inc.
Fulgent Pharma LLC.
M.D. Anderson Cancer Center
Gilead Sciences
UNC Lineberger Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Yonsei University
Washington University School of Medicine
University of California, San Diego
UNC Lineberger Comprehensive Cancer Center
Emory University
Aveta Biomics, Inc.
ImmunityBio, Inc.
Canadian Cancer Trials Group
Tianjin Medical University Cancer Institute and Hospital
GlaxoSmithKline
Incyte Corporation
Brigham and Women's Hospital
Washington University School of Medicine
University of Cincinnati
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Universität des Saarlandes
Pfizer
Washington University School of Medicine
BeiGene
National Institutes of Health Clinical Center (CC)
University of Chicago
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
University of Pittsburgh
Groupe Oncologie Radiotherapie Tete et Cou
Fudan University
ALX Oncology Inc.
ALX Oncology Inc.
University of Maryland, Baltimore
Oslo University Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
National Cancer Centre, Singapore
Thomas Jefferson University
Peking University Hospital of Stomatology
Groupe Oncologie Radiotherapie Tete et Cou
Washington University School of Medicine
Regeneron Pharmaceuticals